テキストサイズ

  • テキストサイズ 中
  • テキストサイズ 大

JP

検索

EN

Menu

閉じる

呼吸器内科学/内科学教室(呼吸器内科学部門)

呼吸器内科学HP http://kokyu-kpum.com/

大学院科目名 呼吸器内科学
医学部教室名 内科学教室(呼吸器内科学部門)
スタッフ
教授  髙山 浩一
 
准教授    山田  忠明
学内講師   金子 美子
助教     徳田 深作
助教     岩破 將博
助教     森本 吉恵
研究内容
当科では、呼吸器疾患を研究対象に、その本態解明および新規診断・治療法開発を目指した基礎・橋渡し・臨床研究を精力的に進めています。また国内外の研究施設との共同研究を行っております。主な研究テーマは以下となります。
1)肺がん分子標的治療耐性に関する研究
2) がん悪液質に関する研究
3) 喫煙による薬剤感受性に関する研究
4) がん免疫治療に関する研究
5) がん微小環境に関する研究
6) 慢性呼吸不全に関する研究
研究業績
(2020年の主な業績)
1) Mouri T, et al. Education Program for Male Patients with Chronic Obstructive Pulmonary Disease to Change Dietary Behavior.
Kobe J Med Sci. 2020 Oct 12;66(3):E82-E89.
 
2) Nishioka N, et al. Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer.
Cancer Med. 2021 Jan;10(1):247-256.
 
3) Morimoto K, et al. Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients.
Med Oncol. 2020 Nov 11;37(12):111.
 
4) Katayama Y, et al. Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients.
Sci Rep. 2020 Oct 15;10(1):17495.
 
5) Hamashima R, et al. Association of immune checkpoint inhibitors with respiratory infections: A review.
Cancer Treat Rev. 2020 Nov;90:102109.
 
6) Wang R, et al. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Nat Commun. 2020 Sep 14;11(1):4607.
 
7) Ikeda K, et al. Diverse Receptor Tyrosine Kinase Phosphorylation in Urine-Derived Tubular Epithelial Cells from Autosomal Dominant Polycystic Kidney Disease Patients.
Nephron. 2020;144(10):525-536.
 
8) Sakakida T, et al. Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies.
Oncol Lett. 2020 Oct;20(4):14.
 
9) Matsui Y, et al. Advanced G-CSF-producing non-small cell lung cancer-not otherwise specified, with favourable response to pembrolizumab monotherapy.
Respirol Case Rep. 2020 Jul 16;8(7):e00625.
 
10) Kaneko Y, et al. The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status.
Intern Med. 2020;59(13):1605-1610.
 
11) Okura N, et al. Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review.
J Clin Med. 2020 Jun 29;9(7):2033.
 
12) Kobayashi K, et al. Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.
Lung Cancer. 2020 Aug;146:236-243.
 
13) Igawa S, et al. Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.
Lung Cancer. 2020 Aug;146:160-164.
 
14) Yamada T, et al. Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).
Ther Adv Med Oncol. 2020 May 28;12:1758835920927841.
 
15) Nakao A, et al. Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment.
J Clin Med. 2020 Jun 5;9(6):1762.
 
16) Takayama K, et al. Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
Oncologist. 2020 Aug;25(8):e1146-e1157.
 
17) Onoi K, et al. Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
J Clin Med. 2020 May 6;9(5):1362.
 
18) Takayama K, et al. Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Oncologist. 2020 Mar;25(3):208-e417.
 
19) Chihara Y, et al. Histone deacetylase inhibitor OBP‑801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1‑dependent apoptosis.
Int J Oncol. 2020 Mar;56(3):848-856.
 
20) Sekine I, et al. A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients.
Cancer Sci. 2020 May;111(5):1685-1691.
 
21) Kaneko Y, et al. Respiratory complications of Stevens-Johnson syndrome (SJS): 3 cases of SJS-induced obstructive bronchiolitis.
Allergol Int. 2020 Jul;69(3):465-467.
 
22) Okura N, et al. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Clin Cancer Res. 2020 May 1;26(9):2244-2256.
 
問い合わせ先 TEL:075-251-5513
FAX:075-251-5376
e-mail:takayama@koto.kpu-m.ac.jp
教室独自のHP http://kokyu-kpum.com/

〒602-8566. 京都市上京区河原町通広小路上る梶井町465

お問い合わせ先
TEL:075-251-5111
FAX:075-211-7093